Antibody-immunotherapy combination shows promise in lung cancer6 December 2023 | By Catherine Eckford (European Pharmaceutical Review)A study evaluating the combination of a PD1 inhibitor with dupilumab enabled one out of six lung cancer patients to achieve a near-complete clinical response two months post-treatment, a paper states.
Novartis secures first-of-a-kind haematology approval6 December 2023 | By Catherine Eckford (European Pharmaceutical Review)A novel Factor B inhibitor of the immune system's complement pathway has been approved for paroxysmal nocturnal haemoglobinuria (PNH).
UK’s entrance into Horizon Europe finalised5 December 2023 | By Catherine Eckford (European Pharmaceutical Review)The EU-UK Specialised Committee on Participation in Union Programmes has adopted the political agreement on UK’s association to the Horizon Europe programme.
Roche to advance novel obesity and diabetes treatments5 December 2023 | By Catherine Eckford (European Pharmaceutical Review)The assets Roche will gain rights to through its planned acquisition of Carmot Therapeutics include several incretin treatments with best-in-class potential in obesity and diabetes.
Phase III data for novel telomerase inhibitor released5 December 2023 | By Catherine Eckford (European Pharmaceutical Review)Currently, imetelstat is being reviewed by the FDA and EMA for the treatment of transfusion-dependent anaemia in adults with lower risk MDS.
Pharmaceutical excipients market to witness expansion4 December 2023 | By Catherine Eckford (European Pharmaceutical Review)According to research, increased in R&D investment for developing novel excipients and greater emphasis on patient-centric formulations are key drivers for the pharmaceutical excipients market.
Novel generalised myasthenia gravis treatment approved4 December 2023 | By Catherine Eckford (European Pharmaceutical Review)A subcutaneous C5 complement inhibitor has been authorised by the European Commission (EC) as a treatment for generalised myasthenia gravis in Europe.
Survey reports on falsification of medical devices1 December 2023 | ByFalsification of medical devices exists in Council of Europe member states, but there are few investigations and prosecutions, a new survey finds.
AbbVie agrees $10 billion oncology acquisition1 December 2023 | By Catherine Eckford (European Pharmaceutical Review)Under its proposed acquisition of ImmunoGen, AbbVie will gain rights to ELAHERE®, the first antibody-drug conjugate (ADC) approved in ovarian cancer.
Innovative technologies facilitate novel contamination-detection method30 November 2023 | By Catherine Eckford (European Pharmaceutical Review)A new 24-hour sterility testing method combining nanopore sequencing and machine learning could revolutionise sterility assurance in biopharmaceutical manufacturing of cell therapies.
Acquisition deal to back European biosimilars market30 November 2023 | By Catherine Eckford (European Pharmaceutical Review)Following the acquisition from Viatris, Biocon Biologics and its partners state that they will commercialise biosimilar products in 31 European countries.
Ferring reveals long-term data for cancer gene therapy29 November 2023 | By Catherine Eckford (European Pharmaceutical Review)New data from a Phase III gene therapy trial has demonstrated a 90 percent three-year overall survival rate for its participants with a high-risk bladder cancer.
Pharma unites to secure renewable energy in key manufacturing markets29 November 2023 | By Catherine Eckford (European Pharmaceutical Review)The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
Cold storage market to value $383bn by 203228 November 2023 | By Catherine Eckford (European Pharmaceutical Review)The combination of tech innovation, automation, and sustainability is reshaping the landscape of cold storage solutions, research says.
First pill for desmoid tumours approved28 November 2023 | By Catherine Eckford (European Pharmaceutical Review)Approval of the first treatment option for desmoid tumours beyond surgery and radiation has been granted by the US Food and Drug Administration (FDA).
